z-logo
open-access-imgOpen Access
Taking Aim at the Undruggable
Author(s) -
Niamh Coleman,
Jordi Rodón
Publication year - 2021
Publication title -
american society of clinical oncology educational book/educational book
Language(s) - English
Resource type - Journals
eISSN - 1548-8756
pISSN - 1548-8748
DOI - 10.1200/edbk_325885
Subject(s) - druggability , computational biology , drug discovery , drug development , biology , bioinformatics , computer science , drug , pharmacology , genetics , gene
The term “undruggable” is used to describe a protein that is not pharmacologically capable of being targeted; recently, however, substantial efforts have been made to turn these proteins into “druggable” targets. Thus, “difficult to drug” or “yet to be drugged” are perhaps more appropriate terms. In cancer, a number of elusive targets fall into this category, including transcription factors such as STAT3, TP53, and MYC. Pharmacologically targeting these intractable proteins is now a key challenge of modern drug development, requiring innovation and the development of new technologies. In this article, we discuss some of the recent technologic and pharmacologic advances that have underpinned the erosion of the concept of undruggability. We describe recent successes in drugging the undruggable RAS ( KRAS G12C and HRAS), and discuss the advances that have led to the validation of further targets previously believed to be undruggable, such as HIF-2α, BCL-2, MDM2, and MLL. Finally, we look to the future and describe important advances that are likely to have a major impact on targeting undruggable targets, such as the advent of proteolysis-targeting chimeras and protein-protein modulators, which are leading to considerable excitement surrounding the development of cancer targets.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here